PanGenex expands clinical trial sites of its Calci-CLEAR system

PanGenex Corporation (Pink Sheets: PGCX) (“PanGenex” or “the Company”) announced that due to promising pre-clinical results from its clinical trial at the Cardiovascular Institute of the South (http://www.cardio.com/site1.php), the Company will extend its trial to two additional sites.

The Company initiated a 100 patient, placebo based, double blind clinical trial at the CardioVascular Institute of the South. Early results with only a handful of patients have encouraged the Company to expand this trial.

The clinical trial involves a protocol to test its product Calci-CLEAR, a two part system designed to cleanse and remove calcium deposits from soft tissues such as veins and arteries. The study entails baseline coronary arterial calcium (CAC) scans, bone mineral density scans (DXA), and normal blood lipid and inflammatory markers. Under the protocol, patients are screened and then placed on the product for a period of 5 months. Following the study duration, follow up CAC, DXA, and lab tests are collected. Dr. Peter Fail, the principle investigator for the trial, indicated that one patient experienced a greater than 50% reduction in CAC score following the 5 months of the study.

The results are not statistically significant due to the few completed participants; however the outcome was significant enough to interest two prominent cardiologists and advisory board members to the Company to initiate trials at their respective clinics.

Steve Yakubov, Medical Director of the MidWest Cardiology Research Foundation and Dr. Mark Turco, Cardiovascular Consultants, PA are both preparing to initiate the clinical protocols at their sites.

“The data is slight, however, there is no other natural product available to my knowledge that has this significant of an effect on CAC scores…and to see these types of results is truly exciting.” stated PanGenex Director Dr. Ronald Caputo.